MDGL — MADRIGAL PHARMACEUTICALS, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1157601 ·
Last close
$476.89
Market Cap
$11.00B
52W High
$572.20
52W Low
$421.55
ADV30
282,440
Next earnings
2026-08-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 311,337,000 | 284,490,000 | -92,723,000 | -94,391,000 | 1,227,327,000 | 227,033,000 | 683,873,000 |
| Dec 2025 | 321,083,000 | 296,635,000 | -59,609,000 | -58,575,000 | 1,259,589,000 | 198,693,000 | 656,900,000 |
| Sep 2025 | 287,268,000 | 269,146,000 | -113,975,000 | -114,190,000 | 1,362,457,000 | 295,694,000 | 736,725,000 |
| Jun 2025 | 212,802,000 | 203,737,000 | -47,202,000 | -42,281,000 | 1,015,381,000 | 186,193,000 | 319,403,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-268,097,000
Investing CF
$60,633,000
Financing CF
$249,673,000
CapEx
$-4,823,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-12.80
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-2,184,857,000
Inventory
$112,070,000
Receivables
$187,356,000
ST Investments
$585,738,000
EBIT TTM
$-282,606,000
Pretax Income TTM
$-309,437,000
Interest Exp TTM
$26,831,000
Analysts
12
Yahoo Snapshot (yfinance, live)
Total Revenue
$1,132,489,984
EBITDA
$-311,996,000
Free Cash Flow
$-156,403,504
Enterprise Value
$10,307,988,480
Total Cash
$812,771,008
Total Debt
$347,311,008
Shares Out
23,055,659
Trailing EPS
$-13.49
Book Value
$23.59
ROE
-49.3%
ROA
-17.6%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 958,403,000 | -300,097,000 | -288,284,000 | 1,259,589,000 | 656,900,000 | — | -189,553,000 |
| Dec 2024 | 180,133,000 | -497,875,000 | -465,892,000 | 1,042,247,000 | 287,864,000 | — | -455,572,000 |
| Dec 2023 | 0 | -380,496,000 | -373,630,000 | 640,547,000 | 235,214,000 | — | -324,230,000 |
| Dec 2022 | 0 | -293,571,000 | -295,350,000 | 362,572,000 | 165,183,000 | — | -224,857,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$12.38
Max Pain — expiry 2026-12-18
max pain strike: $540.00 · spot: $476.89 · call oi: 961 · put oi: 653
Expected Move to 2026-12-18:
±$200.82
(42.11%) —
implied range
$276.07 –
$677.71
· ATM straddle on $480.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| SMMT | Summit Therapeutics Inc. | $11.09B | $14.29 | — |
| RDY | DR REDDYS LABORATORIES LTD | $11.13B | $13.37 | — |
| BMRN | BIOMARIN PHARMACEUTICAL INC | $11.19B | $57.91 | — |
| ARWR | ARROWHEAD PHARMACEUTICALS, INC. | $10.33B | $73.33 | — |
| ELAN | Elanco Animal Health Inc | $12.24B | $24.50 | — |
News headlines (Yahoo Finance, 1h cache)
The Bull Case For Madrigal Pharmaceuticals (MDGL) Could Change Following New Rezdiffra Cardiometabolic Data Release
2026-06-09 06:14 · Yahoo
Madrigal (MDGL) Down 7.9% Since Last Earnings Report: Can It Rebound?
2026-06-05 15:30 · Yahoo
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
2026-06-04 20:05 · Yahoo
Madrigal (MDGL) Data Highlights Rezdiffra’s Cardiometabolic Benefits for MASH Patients at EASL Congress
2026-06-04 09:07 · Yahoo
Madrigal Pharmaceuticals to Participate in the 47th Annual Global Goldman Sachs Health Care Conference 2026
2026-06-03 12:00 · Yahoo
Assessing Madrigal Pharmaceuticals (MDGL) Valuation After Recent Share Price Weakness
2026-06-02 22:08 · Yahoo
Why This Fund Made a $189 Million Bet on Erasca as Shares Skyrocket 800%
2026-05-30 00:47 · Yahoo
Tango Therapeutics Stock Is Up 840%, and This Fund Just Disclosed Buying $164 Million More
2026-05-30 00:41 · Yahoo
Madrigal Presents Data Demonstrating Rezdiffra Reduced Markers of Cardiovascular and Liver-Related Risk in Patients with MASH
2026-05-27 12:00 · Yahoo
Madrigal to Present New Data from the Company’s MASH Program at EASL 2026 Demonstrating the Effects of Rezdiffra on Markers of Cardiovascular and Portal Hypertension Risk
2026-05-20 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.